In heart patients with apnea but no sleepiness, CPAP still improved cardiac features
Nearly twice as many CPAP-treated patients saw their HFpEF-like markers improve at one year compared with those who went untreated — in a population sleep specialists have historically deprioritized for treatment.
Patients with obstructive sleep apnea but no significant daytime sleepiness have historically been considered lower priority for CPAP treatment, since sleepiness has long been the main symptom guiding treatment decisions and the clearest marker most trials use to show benefit. A randomized trial published this month in Sleep Medicine, using data from the RICCADSA cohort, tests whether CPAP still delivers a specific cardiac benefit in this "nonsleepy" population [s1].
The design
Researchers analyzed 177 revascularized coronary artery disease patients with nonsleepy obstructive sleep apnea — defined as an Epworth Sleepiness Scale score under 10 (a validated cutoff for clinically significant daytime sleepiness) combined with an apnea-hypopnea index of 15 or higher — who had been randomized in the RICCADSA cohort to CPAP (n=89) or no CPAP (n=88) [s1]. The trial's outcome of interest was heart failure with preserved ejection fraction (HFpEF)-like status, defined using a composite of five echocardiographic and biomarker criteria, with two or more positive criteria counted as HFpEF-like [s1]. Multivariable logistic regression assessed the association between CPAP therapy and HFpEF improvement at 12 months, adjusting for age, sex, BMI, apnea severity, hypertension, diabetes, a heart-strain biomarker (NT-proBNP), and a measure of diastolic heart function (E/e' ratio) [s1].
What it found
HFpEF-like features were common in this population at baseline: present in 126 of 177 patients (71.2%), with similar prevalence in the CPAP (69.7%) and no-CPAP (72.7%) groups going in [s1]. Among patients with HFpEF-like status at baseline, improvement at 12-month follow-up occurred in 24 of 62 patients (38.7%) randomized to CPAP, compared with 13 of 64 patients (20.3%) in the no-CPAP group — a statistically significant difference (p = 0.023) [s1]. In multivariable analysis, CPAP therapy remained independently associated with HFpEF improvement, with an odds ratio of 2.85 (95% CI 1.13–7.22, p = 0.027) [s1]. Higher baseline NT-proBNP, indicating greater underlying cardiac strain, was inversely associated with improvement (odds ratio 0.37, p = 0.002), meaning patients with more severe baseline heart strain were less likely to see improvement regardless of CPAP treatment [s1].
Why treating "nonsleepy" apnea for a cardiac reason is the notable part
Most CPAP trials have used symptom relief — reduced daytime sleepiness — as their primary justification and outcome measure, and patients without significant sleepiness have often been given lower treatment priority in clinical practice as a result, partly because earlier large trials specifically in nonsleepy populations failed to show CPAP prevented major cardiovascular events like heart attack or stroke. This trial tests something narrower and more specific: not whether CPAP prevents a major cardiac event, but whether it can reverse an intermediate, measurable cardiac dysfunction phenotype (HFpEF-like features) in this same nonsleepy population — a more modest but still clinically meaningful question, and one where this trial found a positive signal.
What the NT-proBNP finding suggests about who benefits most
The finding that higher baseline cardiac strain (NT-proBNP) predicted less improvement, independent of CPAP treatment, points toward a specific window of opportunity: the trial's authors frame this as identifying a "potentially modifiable HFpEF phenotype" among patients with lower myocardial stress specifically [s1] — suggesting CPAP's cardiac benefit in this context may be most detectable, or most achievable, before heart strain has progressed too far, rather than as a treatment that reliably reverses more advanced cardiac dysfunction.
What this doesn't establish
This is a secondary analysis of a composite, intermediate outcome (HFpEF-like features assessed via echocardiography and biomarkers) drawn from an existing cohort, not a trial with hard clinical endpoints like heart failure hospitalization or death as its primary measure — meaningful cardiac outcomes that a positive result on this composite marker doesn't guarantee will follow. The sample size, 177 patients with 126 meeting HFpEF-like criteria at baseline, is modest for detecting effects on a composite outcome, and the analysis specifically studied patients who had already undergone coronary revascularization, a population that may not represent sleep apnea patients with coronary disease more broadly.
What to watch
Whether this reversible HFpEF-like phenotype translates into fewer downstream heart failure hospitalizations or improved survival in longer-term follow-up, and whether the finding is replicated in an independent trial designed with hard cardiac endpoints as the primary outcome. This article is not medical advice.
Sources
Sources
More on
Patients with insomnia and apnea saw a bigger blood-pressure drop from CPAP
After four weeks, the comorbid-insomnia group's blood pressure fell 20 points more than the apnea-only group. The finding flips the usual framing of COMISA as simply a worse-outcomes phenotype.
CPAP still outperforms mouth-guard alternatives, but the size of the gap is unclear
Pooling eight trials, oral appliances left nearly 12 more breathing events per hour than CPAP. But the trials disagreed with each other so much that the researchers say that number itself should be read with caution.
On night one, fixed CPAP preserved sleep continuity better than the auto version
Both machine types cut breathing interruptions equally well in a 108-patient study. But auto-adjusting PAP's constantly shifting pressure came with more time awake and less total sleep on night one.
A beta blocker blunted sleep apnea's heart-rate spikes, but cost some sleep quality
Researchers deliberately withdrew CPAP for three nights to simulate untreated sleep apnea, then tested propranolol against placebo. It slowed the heart-rate surges tied to apnea events, at the price of lighter sleep.